



## Dr Lim Kah Meng

CEO of Zenic Labs

Dr Lim received his PhD in 2002. His work involved cell growth, regulation in cancer, infectious diseases, and biomedicine product development. As an entrepreneur, Dr Lim started Gene Oasis, one of the first few of Singapore's branded biotechnology companies.

Dr Lim has started, developed, and nurtured several successful businesses in the biotechnology space, resulting in multimillion-dollar valuations and revenue.

### Particulars

#### Contact

E. [KahMeng@ZenicLabs.com](mailto:KahMeng@ZenicLabs.com)

#### Education

Ph.D. (Biomedicine), National University of Singapore, Singapore

#### Key Expertise:

Biotechnology commercialisation;  
Biomedicine product development;  
Investor attraction; and  
Marketing and sales process.

#### In Media

[Spirit of Enterprise  
Science Magazine  
MACT Symposium](#)

### Curriculum Vitae

#### Experiences:

- 20 years of experience in life sciences research field;
- Professor at Tianjin University (China);
- Professor at Nanyang Technology University (Singapore);
- President of the South East Asia Bird's Nest Chamber of Commerce; and
- Founders and CEO of Gene Oasis Group, which collaborates with A\*STAR's Bioprocessing Technology institute (BTI).

#### Achievements:

- Winner of Singapore Spirit of Enterprise Award (2011);
- Winner of National Conference Research Science Award;
- Winner of International Cancer Research Award at Singapore Annual Oncology Symposium; and
- 52 Patents, granted in Biotech Farming (3), Material Authentication (9), Processing (2), Extraction (19), Composition (9), Purification (3), and Cellular Delivery (7).

#### Selected Publications:

- Effects of High Doses of Vitamin C on Cancer Patients in Singapore. Raymond Yuen, Glenda Chong, Lim Kah Meng, Sage Journal, 2015;
- Antisense abrogation of DENN expression induces apoptosis of leukaemia cells in vitro, causes tumour regression in vivo and alters the transcription of genes involved in apoptosis and the cell cycle. Lim, K.M.; Yeo, W.S.; Chow, V.T.K, NUS, 2004; and
- Induction of marked apoptosis in mammalian cancer cell lines by antisense DNA treatment to abolish expression of DENN (Differentially Expressed in Normal and Neoplastic Cells). Lim, K.M.; Chow, V.T.K. NUS, 2002.

#### Companies Founded & Managed:

- Gene Oasis EBN BioSciences Group (CEO) – Revenue of USD 75 million, attracted investment of USD 35 million;
- Riwai International (CSO) – Revenue of USD 70 million;
- Extend International (CSO) – Revenue of USD 10 million;
- Gene Oasis BioScientific (CEO) – Attracted investment of USD 100 million; and
- FEGO Biotech (CEO) – Attracted investment of USD 500K.